No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

in StudyGraphics

Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Chronic Disease

2 Minute Medicine: Pharma Roundup – Breakthrough ALS gene therapy, new adult pneumonia vaccine, needle-free obesity treatment, and Pfizer’s business overhaul [October 28, 2025]

October 29, 2025

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial

October 22, 2025

Population-based risk factors and geographical trends identified for vitiligo

Oncology

Increasing cancer incidence rates in younger and older adults worldwide

October 20, 2025

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Chronic Disease

Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study

October 13, 2025

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

Patient Basics: Middle-Ear Infection (Otitis Media)

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

RELATED REPORTS

Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

RelatedReports

Recent Reports